CSPC PHARMA (01093.HK) said its Phase III HEALER study of Anbenitamab plus HB1801 showed 24-month PFS of 58.5% vs 34.4%, a 54% lower risk of progression.
ALPHAMAB-B (09966.HK) said Cohort B of its first-line HER2+ GC/GEJ study achieved a 100% confirmed ORR, while JSKN003 in PROC showed a median OS of 23.5 months.
NEXCHIP (02249.HK) said shareholder Huaqin Telecom Hong Kong plans to buy 15-25 million H shares within three months from 27 October 2026 using its own funds.
ROBOTECHNIK (03757.HK) announced its H shares joined the Stock Connect eligible securities list from 26 October 2026, expanding its investor base.
DAJIN (01081.HK) said chairman Jin Xin proposed a buyback of up to 10% of issued H shares, to be cancelled or held as treasury shares, funded by own funds.
CR BLDG MAT TEC (01313.HK) signed a framework agreement with CR Power to buy fly ash, desulfuration gypsum and furnace slag, annual cap RMB40 million.
DUALITYBIO-B (09606.HK) said DYNASTY-Breast02 met its primary endpoint with a modest PFS gain; OS data were immature and ILD rates were higher than before.
October 26, 2026, INNOCARE(09969.HK) released its Nine-Month Report for the period ended December 31, 2026, Total Revenue stood at CNY 2.1 billion, increased by 88.21% YoY
October 26, 2026, ZTE(00763.HK) released its Nine-Month Report for the period ended December 31, 2026, Total Revenue stood at CNY 116.84 billion, increased by 16.23% YoY
COSMO LADY (02298.HK) said executive director Wu Xiaoli bought 1.22 million shares on-market at an average HK$0.2439, about 0.05% of issued shares.
ILUVATAR COREX (09903.HK) has been granted aggregate banking facilities of over RMB12 billion by various banks, with over 80% of the facilities unutilized.
CBHB (09668.HK) issued RMB7 billion of 2026 Tranche 2 financial bonds in the inter-bank market, a three-year fixed rate issue at a 1.55% coupon.
TRIGIANT's Jiangsu unit is a prospective winner of China Tower's 2026 copper power cable centralised tender at about RMB325.8 million, ranking No.4.
On October 26, 2026, GUAN CHAO HLDGS (01872.HK) terminated its operations service agreement with effect from September 11; AI comb sales reached only about RMB301,300 as at September 30 and the business will be discontinued entirely.
On October 26, 2026, LEADS BIOLABS-B (09887.HK) reported ESMO 2026 data for LBL-024, with median OS of 8.7 months in third-line or later EP-NEC, a 12-month OS rate of 39.4% and an ORR of 70.0% in first-line BTC.
On October 26, 2026, PICC GROUP (01339.HK) said the NFRA has approved Zhang Zhongmin's qualification as a non-executive director, effective October 20, alongside membership of two board committees.
